<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02496520</url>
  </required_header>
  <id_info>
    <org_study_id>DEND/TIA</org_study_id>
    <secondary_id>2013-003632-71</secondary_id>
    <nct_id>NCT02496520</nct_id>
  </id_info>
  <brief_title>Dendritic Cell-based Immunotherapy for Advanced Solid Tumours of Children and Young Adults</brief_title>
  <acronym>DEND/TIA</acronym>
  <official_title>Dendritic Cell-based Immunotherapy for Advanced Solid Tumours of Children and Young Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clinica Universidad de Navarra, Universidad de Navarra</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Clinica Universidad de Navarra, Universidad de Navarra</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase I/II, open, prospective clinical trial, historically controlled. The objective is to
      evaluate the safety and, as a secondary measure, the efficacy of an experimental treatment
      based on a cellular therapy (vaccination with autologous dendritic cells pulsed with tumor
      lysate) in patients affected of metastatic or relapsed sarcomas or (Central Nervous System)
      CNS tumors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase I/II, open, prospective clinical trial, historically controlled. Patients affected of
      metastatic or relapsed sarcomas or (Central Nervous System) CNS tumors will be included. The
      patients will receive standard treatment and experimental treatment based on a cellular
      therapy with vaccination with autologous dendritic cells pulsed with tumor lysate. The
      immunization schedule includes 4 monthly vaccines, 4 bimonthly and quarterly remaining
      vaccines. The vaccines will be administered intradermally in combination with standard
      treatment for each type of tumor.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number and type of adverse events detected in the follow up as a measure of safety and tolerability</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Event free progression, overall survival, time to progression and number and size of existent tumoral lesions as measures of clinical efficacy</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Humoral and cellular immune response as a measure of the immunogenicity of the vaccine.</measure>
    <time_frame>2 weeks to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life measured with QLQ-C30, QLQ-BN20 questionnaires.</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Sarcoma</condition>
  <condition>Central Nervous System Tumor</condition>
  <arm_group>
    <arm_group_label>Vaccines with autologous dendritic cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vaccines with autologous dendritic cells</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>dendritic cells</intervention_name>
    <description>vaccines with dendritic cells pulsed with tumor lysate</description>
    <arm_group_label>Vaccines with autologous dendritic cells</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgery as needed by the patient´s tumor and stage</intervention_name>
    <arm_group_label>Vaccines with autologous dendritic cells</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapy as needed by the patient´s tumor and stage</intervention_name>
    <arm_group_label>Vaccines with autologous dendritic cells</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation therapy as needed by the patient´s tumor and stage</intervention_name>
    <arm_group_label>Vaccines with autologous dendritic cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent

          -  Diagnosis or metastatic or relapsed sarcoma or high grade central nervous system tumor

          -  From 3 to 40 years

          -  Surgery feasibility. In the central nervous system tumors, residual tumor after
             surgery must be minimal.

        Exclusion Criteria:

          -  Toxicity or liver, medullar, renal insufficiency that advise against participation

          -  Pregnant or breast feeding women

          -  Diagnosis of other tumor than basal cell squamous carcinoma of the skin or in situ
             cervix carcinoma

          -  Immunosuppressive treatment

          -  Human Immunodeficiency virus (HIV), hepatitis B, hepatitis C or syphilis infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ana Patiño-García, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CUN</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ana Patiño-García, PhD</last_name>
    <phone>34948255400</phone>
    <phone_ext>4257</phone_ext>
    <email>apatigar@unav.es</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Clinic of Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Patiño-García, PhD</last_name>
      <phone>+34948255400</phone>
      <phone_ext>4257</phone_ext>
      <email>apatigar@unav.es</email>
    </contact>
    <contact_backup>
      <last_name>Susana Inogés, MD, PhD</last_name>
      <phone>+34948255400</phone>
      <phone_ext>5167</phone_ext>
      <email>sinoges@unav.es</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 15, 2015</study_first_submitted>
  <study_first_submitted_qc>July 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2015</study_first_posted>
  <last_update_submitted>October 23, 2017</last_update_submitted>
  <last_update_submitted_qc>October 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>dendritic cell vaccination</keyword>
  <keyword>sarcoma</keyword>
  <keyword>central nervous system tumor</keyword>
  <keyword>childhood</keyword>
  <keyword>adolescent</keyword>
  <keyword>immunotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

